TD has acquired Cowen Inc. Please bookmark TD Securities for further updates.

$193 Million

Atara Biotherapeutics

Follow-on Offering

Bookrunner, May 2020

Atara Biotherapeutics

Atara Biotherapeutics, Inc. is an off-the-shelf, allogeneic T-cell immunotherapy company that is developing transformative therapies for patients with severe diseases including solid tumors, hematologic cancers and autoimmune disease. The Company has several T-cell immunotherapies in clinical development and are progressing a portfolio of next-generation CAR-Ts. The Company’s lead product candidate, tab-cel, is an off-the-shelf, allogeneic T-cell im­­munotherapy for patients with Epstein-Barr virus associated post-transplant lymphoproliferative disorder (EBV+ PTLD), a rare b-cell lymphoma that occurs in immunosuppressed patients after transplant, as well as other EBV associated hematologic and solid tumors.